Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in the sex ratio are a good indicator of changes in MS incidence - No

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. A free and simple computerized screening test for visual field defects

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dorothea Buck
  • Till Fm Andlauer
  • Wilmar Igl
  • Eva-Maria Wicklein
  • Mark Mühlau
  • Frank Weber
  • Karl Köchert
  • Christoph Pohl
  • Barry Arnason
  • Giancarlo Comi
  • Stuart Cook
  • Massimo Filippi
  • Hans-Peter Hartung
  • Douglas Jeffery
  • Ludwig Kappos
  • Frederik Barkhof
  • Gilles Edan
  • Mark S Freedman
  • Xavier Montalbán
  • Bertram Müller-Myhsok
  • Bernhard Hemmer
  • BEYOND and BENEFIT Study Groups
  • Jette Lautrup Battistini Frederiksen (Member of study group)
View graph of relations

BACKGROUND: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β.

OBJECTIVE: To validate the proposed genetic markers and to identify new markers.

METHODS: Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon β-1b in the Betaferon® Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseron®/BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials. All patients were treated with interferon β-1b for at least 6 months. In addition, a genome-wide association study was conducted to identify new genetic variants.

RESULTS: We confirmed an increased risk for carriers of HLA-DRB1*04:01 (odds ratio (OR) = 3.3, p = 6.9 × 10-4) and HLA-DRB1*07:01 (OR = 1.8, p = 3.5 × 10-3) for developing neutralizing antibodies (NAbs). Several additional, previously proposed HLA alleles and genetic variants showed nominally significant associations. In the exploratory analysis, variants in the HLA region were associated with NAb development at genome-wide significance (OR = 2.6, p = 2.30 × 10-15).

CONCLUSION: The contribution of HLA alleles and HLA-associated single-nucleotide polymorphisms (SNPs) to the development and titer of antibodies against interferon β was confirmed in the combined analysis of two multi-national, multi-center studies.

Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume25
Issue number4
Pages (from-to)565-573
Number of pages9
ISSN1352-4585
DOIs
Publication statusPublished - 2019

    Research areas

  • anti-drug antibodies, genetic variation, genome-wide association study, HLA-DRB1, interferon beta, Multiple sclerosis

ID: 56667385